Ipsen opens a Cambridge R&D hub; Allergan's Pyott pockets $534M;

@FierceBiotech: Prepping for a Duchenne study, Catabasis banks $12.4M in new fundraising. News | Follow @FierceBiotech

@JohnCFierce: Yale team says failed AstraZeneca drug shows promise in Alzheimer's. FierceBiotechResearch story | Follow @JohnCFierce

@DamianFierce: Serious question: Is the $SRPT hold muzak an instrumental of "I'm all out of love / I'm so lost without you?" | Follow @DamianFierce

> France's Ipsen cut the ribbon on its new Cambridge, MA, R&D center, a hub the company hopes will help it expand its presence in the U.S. biopharma market. News

> Kala Pharmaceuticals said KPI-121, its nanoparticle treatment for inflammation and pain, met its primary goals in a Phase III study in patients who had undergone cataract surgery. Release

> Former Allergan CEO David Pyott pocketed $534 million when Actavis ($ACT) acquired his company, cashing in shares and coasting on a golden parachute. More

Medical Device News

@FierceMedDev: Hansen eyes expansion for robotic surgery system with Chinese distribution deal. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI: Philips brings in former Hologic CEO to head imaging biz in ongoing HealthTech revamp. Article | Follow @StacyALawrence

@VarunSaxena2: Japanese researchers study carbon nanotubes with drug delivery applications. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Get this week's ed. of FierceDiagnostics, feat. 23andMe's first foray into retail, $DGX and $Q's JV, and more. Issue | Follow @EmilyWFierce

> Sony sells off half its Olympus stake amid duodenoscope pushback. Report

> World's largest orthopedics contract manufacturer closing two plants. Story

> Orthofix ($OFIX) restates earnings, gains option to buy migraine device startup eNeura for $65M. More

> Boston Scientific ($BSX) recalls its Expel biliary catheters after complaints of fragmentation. Article

Pharma News

@FiercePharma: Teva used kickbacks to boost Copaxone, Azilect scripts, feds say. FiercePharmaMarketing article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharma: Genentech expansion adds to Roche biologics buildout. It promises 100 jobs, $125M outlay. Story | Follow @EricPFierce

@CarlyHFierce: Final Four time: Four names, one crown: Trulicity, Vimizim star in the #FierceMadness Final Four push. Vote! | Follow @CarlyHFierce

> Celltrion revs up Remicade biosim for U.S. rollout this year. Report

> Takeda offers $2.5B to settle Actos cases, sources tell Bloomberg. Article

Biotech Research News

> IL-17 may guard against skin infections in alcoholics. More

> Google-backed ($GOOG) Calico in-licenses UCSF scientist's work on cognition. Report

> Professional societies flag key areas for COPD research. Item

> Yale team says failed AstraZeneca ($AZN) drug shows promise in Alzheimer's. Story

> Michigan investigators improve on a new approach to acute leukemia. Article

Diagnostics News

> Quest ($DGX) and Quintiles ($Q) team up for JV aimed at clinical research, diagnostics. News

> White House calls for advancing rapid diagnostics to combat drug-resistant bacteria. More

> Bayer signs cardiovascular genomics alliance with Harvard, MIT. Report

> 23andMe dives into retail with U.K. deal for personal genome service. Story

> Cancer Dx startup Helomics joins U.K. genomics initiative alongside big biopharmas. Article

Pharma Marketing News

> Teva ($TEVA) used kickbacks to boost Copaxone, Azilect scripts, feds say. News

> Celltrion eyes biosim Remicade launch in the U.S. this year. Item

> Vivus ($VVUS) to slash obesity salesforce by one-third, turn to digital instead. Report

> Tiny Egalet scouting for 60 reps to hawk its new pain meds. Article

> Forget fighting over Flonase ads. GSK and J&J settle on fight for market share. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.